AMH Equity Ltd Takes $1.14 Million Position in Health Catalyst, Inc. (NASDAQ:HCAT)

AMH Equity Ltd purchased a new stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 252,500 shares of the company’s stock, valued at approximately $1,144,000. Health Catalyst makes up approximately 1.7% of AMH Equity Ltd’s portfolio, making the stock its 21st largest position. AMH Equity Ltd owned 0.36% of Health Catalyst as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of HCAT. Quantbot Technologies LP purchased a new position in shares of Health Catalyst during the 4th quarter valued at $29,000. Group One Trading LLC boosted its holdings in Health Catalyst by 107.6% in the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock worth $31,000 after purchasing an additional 2,260 shares in the last quarter. Aquatic Capital Management LLC bought a new stake in Health Catalyst in the fourth quarter worth $63,000. Martin Worley Group bought a new stake in Health Catalyst in the fourth quarter worth $78,000. Finally, Brevan Howard Capital Management LP bought a new stake in Health Catalyst in the fourth quarter worth $92,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HCAT has been the subject of a number of recent research reports. BTIG Research cut shares of Health Catalyst from a “buy” rating to a “neutral” rating in a report on Tuesday, June 17th. KeyCorp decreased their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, April 16th. Stifel Nicolaus upped their price objective on shares of Health Catalyst from $5.00 to $5.50 and gave the stock a “hold” rating in a report on Thursday, May 8th. Citigroup cut their target price on shares of Health Catalyst from $7.00 to $6.50 and set a “buy” rating for the company in a research report on Friday, April 25th. Finally, Evercore ISI cut their target price on shares of Health Catalyst from $5.00 to $4.00 and set an “in-line” rating for the company in a research report on Wednesday, July 9th. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Health Catalyst presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Health Catalyst Stock Down 2.7%

Shares of HCAT opened at $3.65 on Friday. The company has a 50-day simple moving average of $3.89 and a 200-day simple moving average of $4.56. The firm has a market capitalization of $254.04 million, a P/E ratio of -3.17 and a beta of 1.51. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.24 and a current ratio of 1.24. Health Catalyst, Inc. has a 52 week low of $3.49 and a 52 week high of $9.24.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.